Enavatuzumab 依那妥组单抗; PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)|cas:1062149-33-0|西域试剂

Enavatuzumab 依那妥组单抗; PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab),95.0%

产品编号：Bellancom-P99361| CAS NO：1062149-33-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99361	￥3750.00	杭州北京（现货）
Bellancom-P99361	￥9400.00	杭州北京（现货）
Bellancom-P99361	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Enavatuzumab 依那妥组单抗; PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)

产品介绍

Enavatuzumab (PDL192; ABT-361) 是一种人源化 IgG1 单克隆抗体，靶向 TNF 样细胞凋亡弱诱导剂受体 (TWEAK)。TWEAK (Fn14; TNFRSF12A) 是 TWEAK 受体 (TweakR) 的天然配体，可刺激多种细胞反应。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制。Enavatuzumab 可以主动募集和激活骨髓效应细胞来杀死肿瘤细胞。Enavatuzumab 在体外和体内抑制各种人类 TweakR 阳性癌细胞系和异种移植物的生长。

生物活性

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

体外研究

Enavatuzumab (0.1-1000 ng/mL; 4 小时) 在体外诱导效应细胞活化和肿瘤细胞杀伤。
Enavatuzumab (10μg/mL; 24 小时) 导致免疫效应细胞向 SN12C 和 A375 肿瘤细胞的迁移显着增加。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Renal carcinoma cell line SN12C, the melanoma cell line A375, the colorectal cancer cell lines HCT116 and DLD-1
Concentration:	0.1, 1, 10, 100, 1000 ng/mL
Incubation Time:	4 hours
Result:	Showed potent tumor cell killing on all TweakR-positive tumor cells tested.

体内研究
(In Vivo)

Enavatuzumab (10mg/kg; 腹腔注射; 每周 3 次; 6, 7 或者 9 剂) 对不同的异种移植肿瘤表现出不同的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors
Dosage:	10 mg/kg
Administration:	IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model)
Result:	Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro. Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro. Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice.

体内研究

Enavatuzumab (10mg/kg; 腹腔注射; 每周 3 次; 6, 7 或者 9 剂) 对不同的异种移植肿瘤表现出不同的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors
Dosage:	10 mg/kg
Administration:	IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model)
Result:	Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro. Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro. Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice.

体内研究

Enavatuzumab (10mg/kg; 腹腔注射; 每周 3 次; 6, 7 或者 9 剂) 对不同的异种移植肿瘤表现出不同的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors
Dosage:	10 mg/kg
Administration:	IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model)
Result:	Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro. Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro. Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice.